|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 26, 2009. Amortized
revenue — Adalat/Avinza
Amortized revenue was $4.5 million in 2007 and
$30.7 million in 2006. The amortized revenue recorded in
2007 was related to the licensing to Watson Pharmaceuticals,
Inc. in 2002 of rights to our generic form of Adalat CC (2006:
$9.0 million). The deferred revenue relating to Adalat CC
was fully amortized by June 30, 2007. In 2006, we also
recorded $21.7 million of amortized revenue relating to the
restructuring of our Avinza license agreement with Ligand
Pharmaceuticals, Inc. in 2002. The deferred revenue relating to
Avinza was fully amortized by December 2006.
This excerpt taken from the ELN 20-F filed Feb 28, 2008. Amortized
revenue — Adalat/Avinza
Amortized revenue was $4.5 million in 2007, compared to
$30.7 million in 2006 and $34.0 million in 2005. The
amortized revenue recorded in 2007 was related to the licensing
to Watson Pharmaceuticals, Inc. (Watson) in 2002 of rights to
our generic form of Adalat CC (2006: $9.0 million; 2005:
$9.0 million). The deferred revenue relating to Adalat CC
was fully amortized by June 30, 2007. In 2006, we also
recorded $21.7 million (2005: $25.0 million) of
amortized revenue relating to the restructuring of our Avinza
license agreement with Ligand Pharmaceuticals, Inc (Ligand) in
2002. The deferred revenue relating to Avinza was fully
amortized by December 2006.
Table of Contents
This excerpt taken from the ELN 20-F filed Feb 28, 2007. (C) Amortized
revenue — Adalat/Avinza
Amortized revenue of $34.0 million in both 2005 and 2004
related to the licensing to Watson Pharmaceuticals, Inc.
(Watson) of rights to our generic form of Adalat CC
($9.0 million) and the restructuring of our Avinza license
agreement with Ligand Pharmaceuticals, Inc (Ligand)
($25.0 million). Both of these transactions occurred in
2002. The remaining unamortized revenue on these products of
$35.2 million is included in deferred revenue, due to our
ongoing involvement in the manufacturing of these products. Of
the remaining $35.2 million, $13.5 million of the
deferred revenue relates to generic Adalat CC and will be
recognized as revenue through June 2007. The remaining deferred
revenue of $21.7 million relates to Avinza and will be
recognized as revenue through November 2006.
This excerpt taken from the ELN 20-F filed Mar 30, 2006. (C) Amortized
revenue — Adalat/Avinza
Amortized revenue of $34.0 million in both 2004 and 2003
related to the licensing to Watson of rights to our generic form
of Adalat CC ($9.0 million) and the restructuring of our
Avinza license agreement with Ligand ($25.0 million). Both
of the transactions occurred in 2002. The remaining unamortized
revenue on these products of $69.2 million is included in
deferred revenue, due to our ongoing involvement in the
manufacturing of these products. Of the remaining
$69.2 million, $22.5 million of the deferred revenue
relates to generic Adalat CC and will be recognized as revenue
through June 2007. The remaining deferred revenue of
$46.7 million relates to Avinza and will be recognized as
revenue through November 2006.
| EXCERPTS ON THIS PAGE:
|
| |||||||
